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Despite the strong evidence that ePLND positively affects
survival in men with limited lymph node involvement, this
procedure is not commonly performed. The reasons for this
are multiple and include expertise, stage migration and
functional and oncological outcomes, as well as economics
and the introduction of laparoscopic and laparoscopic RARP.
However, this is no reason not to offer the patient, if possible,
an operation which has the highest chance of cure.
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Does a positive margin always mandate adjuvant
radiotherapy?
The appropriate treatment for clinically localized prostate
cancer continues to generate controversy. For men with low
grade disease it is unclear whether surgery or radiation
therapy provides a survival advantage over active surveillance,
and among men with high grade disease it is unclear how
many derive a substantial benefit from either intervention. No
trial has yet to compare surgery and radiation with
observation, but the recent update of the Scandinavian
Prostate Cancer Group 4 study suggests that radical
prostatectomy provides a significant survival advantage for
younger men with intermediate grade disease [1].
Unfortunately, many men undergoing radical prostatectomy
are not cured of their disease. The Scandinavian Prostate
Cancer Group 4 study has shown that as many as 26% of
men undergoing surgery developed distant metastases and
18% died from their disease after a median follow-up of
13 years. For this reason many clinicians recommend
additional radiation therapy for those men undergoing
surgery who are at high risk of disease recurrence. Three
randomized trials now support the use of radiation therapy in
this setting. Two have shown lower rates of biochemical
progression and one has shown improved distant metastases-
free survival and overall survival [2–4]. These trials compared
the use of adjuvant radiation therapy with observation. Some
clinicians, however, are reluctant to refer patients for
radiation therapy because of concerns about its potential
impact on quality of life. This is especially true for those
patients who have yet to show any evidence of biochemical
recurrence.
In a manuscript published in this month’s BJUI, Hsu et al.
[5] have turned to a large national prostate cancer registry
that has accrued men with newly diagnosed prostate cancer
since 1995. They evaluated the long-term outcomes of these
men to gain insights into whether a delay in the initiation of
radiation therapy compromises survival. Their findings
suggest that delaying the initiation of radiation therapy until
there is evidence of biochemical recurrence does not seriously
compromise long-term outcomes and avoids radiation in
some men who are never destined to have disease
progression.
The authors are appropriately cautious with their conclusions
and clearly recognize the limitations of a non-randomized
study. In a registry study it is impossible to control adequately
for selection biases. Men receiving adjuvant therapy had no
evidence of biochemical recurrence at the time radiation was
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started. This group of men included both men who were
destined to have disease progression and men who were
destined to maintain an undetectable PSA. This differs from
the men receiving salvage radiation therapy. All men receiving
salvage radiation had evidence of disease progression and
therefore their tumour burden and their long-term prognosis
was probably worse when compared with men receiving
adjuvant therapy. Despite this selection bias, men initiating
salvage radiation when their postoperative PSA level was still
<1.0 ng/mL had similar long-term outcomes when compared
with the men receiving adjuvant radiation. Men with
postoperative PSA levels >1.0 ng/mL had a much higher risk
of aggressive disease and a worse outcome.
Ideally, the question about the timing of postoperative
radiation would be subjected to a randomized trial. Until
then, the information provided by Hsu et al. provides strong
clinical support for a practical approach to the question of
who should receive postoperative radiation. Men who are
clearly at high risk of disease progression, which includes
men with Gleason 8–10 disease and those with extensive
margin positive disease and seminal vesicle invasion, should
probably receive adjuvant radiation therapy as soon as they
have recovered from surgery. For men with Gleason 7 disease
or those men who have focal margin-positive disease it may
make sense to monitor postoperative PSA levels closely and
refer men for postoperative radiation when there is evidence
of biochemical progression and before the PSA level reaches
1.0 ng/mL. This approach would spare some men the need
for additional treatment and would defer treatment for many
years in others. Men who are eventually found to have
biochemical recurrence should feel reasonably comfortable
that the delay in initiating radiation therapy is unlikely to
have caused any significant compromise of their long-term
outcome and probably improved their quality of life.
Large case series analyses frequently have selection biases that
confound conclusions. In this instance the authors have
cautiously interpreted a large community-based registry to
gain a valuable insight into the management of localized
prostate cancer. Their analysis provides appropriate support
for their conclusions.
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Is 42 days the ‘magic number’ for repeat
transurethral resection of bladder tumour (TURBT)?
G€okce et al. [1] have evaluated a group of 242 patients from
10 centres with high-risk non-muscle-invasive bladder cancer
(NMIBC) who underwent repeat resection and subsequent
follow-up treatment, including induction and maintenance
BCG for at least 1 year. They included patients who had repeat
transurethral resection (TUR) within 90 days and excluded
anyone who was upstaged to T2 or who did not complete
1 year of maintenance BCG. They divided patients into two
groups according to time to second TUR, Group A (14–
42 days) and Group B (43–90 days). The groups were similar
in terms of patient age and gender, tumour multifocality,
presence of carcinoma in situ (CIS), and stage and grade. The
only factors on multivariable analysis that were statistically
significant predictors of recurrence were grade, associated CIS,
and time to second TUR. Only grade and time to second TUR
were significant predictors of progression.
678
© 2015 The Authors
BJU International © 2015 BJU International
Editor's Choice
